{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:59Z","timestamp":1792225439479,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201500009C"],"award-info":[{"award-number":["HHSN261201500009C"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jmoldx.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T02:05:18Z","timestamp":1555985118000},"page":"718-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA"],"prefix":"10.1016","volume":"21","author":[{"given":"Justin T.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion J.","family":"Beldorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walairat","family":"Laosinchai-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri L.","family":"Jefferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-0424","authenticated-orcid":false,"given":"Adam K.","family":"Ruskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-5144","authenticated-orcid":false,"given":"Richard D.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Hedges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard F.","family":"Andruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2019.03.002_bib1","series-title":"SEER Cancer Statistics Review, 1975-2015","year":"2018"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","article-title":"A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts","volume":"32","author":"Burmeister","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","article-title":"Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia","volume":"13","author":"Jabbour","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"International Randomised Study of Interferon versus STISG: frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jviromet.2008.02.007","article-title":"The use of Armored RNA as a multi-purpose internal control for RT-PCR","volume":"150","author":"Stevenson","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/sim.1525","article-title":"Estimate of standard deviation for a log-transformed variable using arithmetic means and standard deviations","volume":"22","author":"Quan","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib15","series-title":"Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition. CLSI document","year":"2012"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib16","series-title":"Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guidelines","year":"2003"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/bcj.2011.10","article-title":"Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale","volume":"1","author":"Brown","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","author":"White","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","article-title":"Best practices in chronic myeloid leukemia monitoring and management","volume":"21","author":"Soverini","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/00031305.1989.10475612","article-title":"Some implementations of the boxplot","volume":"43","author":"Frigge","year":"1989","journal-title":"Am Stat"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1373\/clinchem.2003.026161","article-title":"Properties of the reverse transcription reaction in mRNA quantification","volume":"50","author":"Stahlberg","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","author":"Wang","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","article-title":"The role of early molecular response in the management of chronic phase CML","volume":"12","author":"Harrington","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib26","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib28","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.clml.2015.07.647","article-title":"Economic burden of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia","volume":"15","author":"Knopf","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib29","first-page":"214","article-title":"Health care resource utilization and costs\u00a0in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency","volume":"23","author":"Latremouille-Viau","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818304136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818304136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:12:38Z","timestamp":1761502358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157818304136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1525157818304136"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.03.002","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}